This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thomas, E. Articles by Hortobagyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Thomas, E. Articles by Hortobagyi, G. N. Social Bookmarking                            What's this?

The Use of Alternate, Non–Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial

From The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Eva Thomas, MD, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030; e-mail: ethomas{at}mdanderson.org

PURPOSE: To evaluate the use of an alternate, non–cross-resistant adjuvant chemotherapy regimen in women with a poor pathologic response to a preoperative doxorubicin-based regimen.

PATIENTS AND METHODS: Patients with locally advanced breast cancer received three cycles of vincristine, doxorubicin, cyclophosphamide, and prednisone (VACP) every 21 days followed by surgery. Patients with less than 1 cm³ residual tumor at mastectomy received an additional five cycles of VACP. Those with more than 1 cm³ residual tumor were randomly assigned to receive an additional five cycles of VACP or five cycles of vinblastine, methotrexate with calcium leucovorin rescue, and fluorouracil (VbMF).

RESULTS: One hundred ninety-three patients were evaluable. Overall clinical response was seen in 83.4% after three cycles of VACP, whereas the pathologic complete response was 12.2%. One hundred six patients were randomly assigned to VACP or VbMF. Those receiving VbMF achieved higher relapse-free survival (RFS) and overall survival (OS) than those who received additional VACP, although the differences did not reach statistical significance. Initial stage of tumor, clinical complete response, and pathologic complete response were all associated with statistically superior survival rates.

CONCLUSION: Clinical and pathologic response to preoperative doxorubicin-based chemotherapy predicted for improved survival in women with operable breast cancer. For those with a poor response to initial neoadjuvant chemotherapy, treatment with VbMF was associated with a trend toward improved RFS and OS compared with those continuing with the doxorubicin regimen.

Supported by the Nylene Eckles Professorship in Breast Cancer Research.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Colleoni, V. Bagnardi, N. Rotmensz, S. Dellapasqua, G. Viale, G. Pruneri, P. Veronesi, R. Torrisi, A. Luini, M. Intra, et al. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer Ann. Onc., July 1, 2009; 20(7): 1178 - 1184. [Abstract] [Full Text] [PDF]

				V. Guarneri, F. Piacentini, G. Ficarra, A. Frassoldati, R. D'Amico, S. Giovannelli, A. Maiorana, G. Jovic, and P. Conte A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy Ann. Onc., July 1, 2009; 20(7): 1193 - 1198. [Abstract] [Full Text] [PDF]

				V. Valero The Role of Systemic Treatment for Patients with Residual Disease after Neoadjuvant Chemotherapy ASCO Educational Book, January 1, 2009; 2009(1): 30 - 33. [Abstract] [Full Text] [PDF]

				H. D. Bear Measuring Circulating Tumor Cells As a Surrogate End Point for Adjuvant Therapy of Breast Cancer: What Do They Mean and What Should We Do About Them? J. Clin. Oncol., March 10, 2008; 26(8): 1195 - 1197. [Full Text] [PDF]

				J. R. Gralow, H. J. Burstein, W. Wood, G. N. Hortobagyi, L. Gianni, G. von Minckwitz, A. U. Buzdar, I. E. Smith, W. F. Symmans, B. Singh, et al. Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease J. Clin. Oncol., February 10, 2008; 26(5): 814 - 819. [Abstract] [Full Text] [PDF]

				W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, M. Green, et al. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy J. Clin. Oncol., October 1, 2007; 25(28): 4414 - 4422. [Abstract] [Full Text] [PDF]

				C. Shimizu, M. Ando, T. Kouno, N. Katsumata, and Y. Fujiwara Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer Jpn. J. Clin. Oncol., January 3, 2007; (2007) hyl122v1. [Abstract] [Full Text] [PDF]

				H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027. [Abstract] [Full Text] [PDF]

				M. Kaufmann, G. N. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris, P. Valagussa, J.-U. Blohmer, W. Eiermann, R. Jackesz, W. Jonat, et al. Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update J. Clin. Oncol., April 20, 2006; 24(12): 1940 - 1949. [Abstract] [Full Text] [PDF]

				A. M. Gonzalez-Angulo, S. E. McGuire, T. A. Buchholz, S. L. Tucker, H. M. Kuerer, R. Rouzier, S.-W. Kau, E. H. Huang, P. Morandi, A. Ocana, et al. Factors Predictive of Distant Metastases in Patients With Breast Cancer Who Have a Pathologic Complete Response After Neoadjuvant Chemotherapy J. Clin. Oncol., October 1, 2005; 23(28): 7098 - 7104. [Abstract] [Full Text] [PDF]

				A. Katz Does Neoadjuvant/Adjuvant Chemotherapy Change the Natural History of Classic Invasive Lobular Carcinoma? J. Clin. Oncol., September 20, 2005; 23(27): 6796 - 6796. [Full Text] [PDF]

				G. Cocconi, B. Di Blasio, C. Boni, G. Bisagni, E. Rondini, M. A. Bella, F. Leonardi, L. Savoldi, C. Vallisneri, R. Camisa, et al. Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes Ann. Onc., September 1, 2005; 16(9): 1469 - 1476. [Abstract] [Full Text] [PDF]

				G. von Minckwitz and S. Loibl In vivo chemosensitivity adapted preoperative chemotherapy in patients with early stage breast cancer: the Gepartrio pilot study Ann. Onc., September 1, 2005; 16(9): 1560 - 1561. [Full Text] [PDF]

				G. Frasci, G. D'Aiuto, P. Comella, R. Thomas, G. Botti, M. Di Bonito, M. D'Aiuto, G. Romano, M. R. Rubulotta, G. Comella, et al. A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study Ann. Onc., August 1, 2005; 16(8): 1268 - 1275. [Abstract] [Full Text] [PDF]